UltraSight Overview
UltraSight’s mission is to make diagnostic imaging more accessible by empowering medical professionals to successfully acquire timely and accurate cardiac ultrasound images anywhere. UltraSight's AI-driven software offers real-time guidance, making cardiac ultrasound accessible and efficient, which may lead to quicker diagnoses and improved patient care. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most “innovative cardiac technology.” Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices. UltraSight’s software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans.
Cumulative Funding Raised Over Time ($)
$2.0MMar 2019
$15.0MMay 2021
$15.0MMay 2024
Latest News
growth-positive
UltraSight collaborates with Mayo Clinic to advance next generation cardiac care with AI
UltraSight, a digital health company specializing in cardiac imaging with artificial intelligence, is partnering with Mayo Clinic to develop algorithms for analyzing and interpreting cardiac ultrasound images. The collaboration aims to create a new solution and decision support to help healthcare providers make more informed diagnoses and treatment decisions using point-of-care ultrasound devices. Mayo Clinic is now an investor in UltraSight and will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
PartnersInvestment
growth-positive
Korean Firm Bringing Israeli Ultrasound Software To Local Market
Israeli startup UltraSight has partnered with South Korean medical device manufacturer Selvas Healthcare to introduce its AI-powered cardiac ultrasound software into the Asian market. The software provides real-time support for cardiac ultrasound imagery, improving diagnoses and patient care. This partnership marks UltraSights first step into the Korean market and includes securing approvals for distribution in the country. Selvas will have exclusive distribution rights to UltraSights technology.
PartnersExpand
growth-positive
FDA Grants Clearance for UltraSight's AI-Powered Cardiac Ultrasound Technology
UltraSight, a digital health company, has received FDA clearance for its AI-powered ultrasound guidance technology. The software assists medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings. This will allow for more widespread detection of heart disease and easier access to cardiac monitoring for patients. UltraSights solution will enable hospital staff to advance patient triage and treatment with increased efficiency and clinical confidence. It can also increase access to care for chronic heart disease patients by bringing cardiac ultrasound into local communities.
InvestmentExpand
growth-positive
UltraSight and EchoNous Partner to Enable More Accessible Cardiac Ultrasound for Patients
UltraSight, a digital health company specializing in cardiac imaging through artificial intelligence, has announced a partnership with EchoNous, a point-of-care ultrasound innovator. The partnership aims to enable more healthcare professionals to perform cardiac ultrasound, thereby increasing patient access to cardiac care. UltraSights real-time AI guidance software will be integrated with EchoNous KOSMOS handheld ultrasound device. The goal is to enable chronic cardiac patient monitoring to be done closer to patients. The partnership was announced at ASE 2023.
Partners
growth-positive
UltraSight Granted Patent for Real-Time Guidance Ultrasound Technology
UltraSight, an Israeli-based digital health pioneer, has been granted a patent for its real-time guidance technology for ultrasound devices. The technology aims to simplify cardiac ultrasound and allow medical professionals with no prior sonography experience to accurately perform echocardiographic examinations. UltraSights guidance software is currently under FDA review. The company has also partnered with The Weizmann Institute of Science and NYU Langone School of Medicine. The patent was granted by the U.S. Patent and Trademark Office (USPTO).
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $15.2M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 4 |
| Investors | 4 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | ultrasight.com |
Locations
Pinhas Sapir St 8, Ness Ziona, Israel
1 Broadway, Cambridge, MA 02142, USA
Photos & Videos
1 item(s)
UltraSight Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Industrial ManufacturingDiscrete IndustriesAerospaceHealthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceMachine LearningTags (13)
software-platformreal-timespace-techdigital-healthcaremedical-devicesartificial-intelligencehealthcare-providersmachine-learningdiagnosticsdeep-neural-networksultrasoundmedical-image-analysiscardiologyGeographic Markets
United StatesEuropeUltraSight Financials
$15.2M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
B
Funding stage
4
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$2.0MMar 2019
$15.0MMay 2021
$15.0MMay 2024
Private Equity Funding
B Round
May 2024
Undisclosed
Iron Nation
B Round
May 2021
$13M
Weizmann Institute of Science, Atain Insurance Companies, The Yozma Group
A Round
Mar 2019
$2M
The Yozma Group
Non-Equity Funding
GrantEvent
Oct 2020
$200K
Cardiovascular Research Foundation (Lead)
UltraSight Lifecycle
Cumulative Funding Raised Over Time
$2.0MMar 2019
$15.0MMay 2021
$15.0MMay 2024
All Events
B Round
May 2024
Undisclosed
Iron Nation
B Round
May 2021
$13M
Weizmann Institute of Science, Atain Insurance Companies, The Yozma Group
A Round
Mar 2019
$2M
The Yozma Group
GrantEvent
Oct 2020
$200K
Cardiovascular Research Foundation (Lead)
UltraSight News
12 articles
growth-positive
UltraSight collaborates with Mayo Clinic to advance next generation cardiac care with AI
UltraSight, a digital health company specializing in cardiac imaging with artificial intelligence, is partnering with Mayo Clinic to develop algorithms for analyzing and interpreting cardiac ultrasound images. The collaboration aims to create a new solution and decision support to help healthcare providers make more informed diagnoses and treatment decisions using point-of-care ultrasound devices. Mayo Clinic is now an investor in UltraSight and will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
PartnersInvestment
growth-positive
Korean Firm Bringing Israeli Ultrasound Software To Local Market
Israeli startup UltraSight has partnered with South Korean medical device manufacturer Selvas Healthcare to introduce its AI-powered cardiac ultrasound software into the Asian market. The software provides real-time support for cardiac ultrasound imagery, improving diagnoses and patient care. This partnership marks UltraSights first step into the Korean market and includes securing approvals for distribution in the country. Selvas will have exclusive distribution rights to UltraSights technology.
PartnersExpand
growth-positive
FDA Grants Clearance for UltraSight's AI-Powered Cardiac Ultrasound Technology
UltraSight, a digital health company, has received FDA clearance for its AI-powered ultrasound guidance technology. The software assists medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings. This will allow for more widespread detection of heart disease and easier access to cardiac monitoring for patients. UltraSights solution will enable hospital staff to advance patient triage and treatment with increased efficiency and clinical confidence. It can also increase access to care for chronic heart disease patients by bringing cardiac ultrasound into local communities.
InvestmentExpand
growth-positive
UltraSight and EchoNous Partner to Enable More Accessible Cardiac Ultrasound for Patients
UltraSight, a digital health company specializing in cardiac imaging through artificial intelligence, has announced a partnership with EchoNous, a point-of-care ultrasound innovator. The partnership aims to enable more healthcare professionals to perform cardiac ultrasound, thereby increasing patient access to cardiac care. UltraSights real-time AI guidance software will be integrated with EchoNous KOSMOS handheld ultrasound device. The goal is to enable chronic cardiac patient monitoring to be done closer to patients. The partnership was announced at ASE 2023.
Partners
growth-positive
UltraSight Granted Patent for Real-Time Guidance Ultrasound Technology
UltraSight, an Israeli-based digital health pioneer, has been granted a patent for its real-time guidance technology for ultrasound devices. The technology aims to simplify cardiac ultrasound and allow medical professionals with no prior sonography experience to accurately perform echocardiographic examinations. UltraSights guidance software is currently under FDA review. The company has also partnered with The Weizmann Institute of Science and NYU Langone School of Medicine. The patent was granted by the U.S. Patent and Trademark Office (USPTO).
PartnersInvestment
growth-positive
New Landmark Study Indicates UltraSight Enables Novice Ultrasound Users to Capture High Quality Cardiac Images
UltraSight, an Israeli-based digital health pioneer, announced new findings from a study that confirm medical professionals without sonography experience can accurately perform echocardiographic examinations using UltraSights AI guidance and quality assessment technology. The study evaluated the performance of nine residents and registered nurses who underwent a one-day training course and successfully acquired high-quality diagnostic images of the heart. The results showed that the exams conducted by the novice users were comparable to those conducted by professional cardiac sonographers. UltraSights technology aims to revolutionize cardiac sonography through the power of machine learning and is currently under FDA review.
Customers
growth-positive
UltraSight Receives CE Mark for Novel Cardiac AI Technology
UltraSight, an Israeli-based digital health pioneer, has obtained a CE Mark for its AI guidance software for cardiac ultrasound. The technology allows medical professionals to capture diagnostic quality ultrasound images of the heart, improving access to optimized cardiac care. The software provides real-time instructions on how to capture high-quality images and predicts the position of the ultrasound probe. The CE Mark milestone aligns with the European Society of Cardiologys goal to achieve heart health in Europe by 2025. UltraSights software is expected to be available in Europe in 2023.
CustomersExpand
growth-positive
UltraSight and GE Healthcare partner to bring cardiac point of care ultrasound to space
UltraSight has announced a collaboration with GE Healthcare to conduct a cardiac study aboard the Axiom Rakia space mission. The aim of the study is to show how accurate cardiac ultrasound images can be obtained from space and how AI guidance can help with successful scanning. The study has the potential to serve underserved patients worldwide. UltraSight was founded in 2018 and has raised $15.2 million over three rounds. GE Healthcare is worth $18 billion and provides intelligent devices, data analytics, applications, and services in the healthcare sector.
Partners
growth-positive
Product Spotlight: UltraSight Cardiac Sonography
UltraSight, an Israeli cardiac imaging company, has developed an ultrasound tool powered by artificial intelligence (AI) software that helps providers capture high-quality cardiac images. The goal is to improve access to cardiac care and prevent avoidable deaths from cardiovascular disease. The AI platform allows doctors and nurses to learn how to capture high-quality images in just one day. The software guides the provider to the optimal image by creating a target with a crosshair guide. The captured images can be sent to cardiologists for timely diagnosis, connecting patients in low-resource areas to expert cardiac care. The tool also benefits radiologists by helping evaluate the cardio-toxic effects of chemotherapy and enabling quicker access to care through triage. UltraSight aims to positively impact patient care and reduce costs through early detection and risk management.
CustomersExpand
growth-positive
UltraSight raises $13 million, bringing AI guidance for cardiac ultrasounds anywhere
UltraSight, a company that automates medical imaging, has raised $13 million in series B funding. The funding will be used to advance its clinical programs in the U.S for real-time, AI guidance for cardiac ultrasounds. The participants in the funding round include The Yozma Group Korea, Atain Specialty Insurance Company, and the Weizmann Institute of Science. UltraSights AI platform enables ultrasound devices to conduct sonography at the point of care, allowing for accurate diagnosis and treatment. The company aims to make ultrasound readily available to assess any patient, anywhere, and by any healthcare professional.
Investment
growth-positive
OnSight Medical wins TCT Connect 2020 Shark Tank Innovation Competition
OnSight Medical, an AI-based company specializing in cardiac ultrasound imaging, has won the TCT 2020 Shark Tank Innovation Competition. The companys software provides real-time, expert level scans with high-quality 4D images, expanding access to cardiac ultrasound in underserved populations. OnSight was presented with the Jon DeHaan Foundation Award for Interventional Innovation. The competition was organized by the Cardiovascular Research Foundation (CRF) during the Transcatheter Cardiovascular Therapeutics (TCT) event. The partnership between CRF and TCT, along with the Jon DeHaan Foundation, aims to support innovative developments in cardiovascular medicine. The article highlights the potential of OnSights AI technology to disrupt the cardiovascular field and improve patient treatment.
PartnersCustomers
growth-positive
https://www.jpost.com/Israel-News/South-Korea-invests-in-Israeli-innovation-584455
South Korean companies, Yozma Group Asia and BioLeaders Corporation, are investing $12 million in Israeli anti-cancer technology developed at the Weizmann institute of Science. Yozma Group Asia will invest $2 million in On-Sight Medical Inc., which is developing an easy-to-use ultrasound technology. BioLeaders is developing an anti-cancer drug based on the discovery that the p53 protein is disabled in two-thirds of cancer types. Israeli scientists have developed a new protein that restores p53 proteins normal functions. The therapy has shown promising results in lab mice with human cancer tumors.
Investment
UltraSight Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 39 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
UltraSight Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 515951267 |
| Crunchbase | on-sight-b615 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-15T00:00:00.000Z |
| Created | 2020-02-26T00:00:00.000Z |
| Claimed | Yes |